PRAXIS PRECISION MEDICINES, INC. Net Income (Loss) Available to Common Stockholders, Basic
PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$167.06 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2022-02-28
- PRAXIS PRECISION MEDICINES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-12-31 was -$58.58M.
- PRAXIS PRECISION MEDICINES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-09-30 was -$44.70M.
- PRAXIS PRECISION MEDICINES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-06-30 was -$36.40M.
- PRAXIS PRECISION MEDICINES, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-03-31 was -$27.37M.
- PRAXIS PRECISION MEDICINES, INC. net income (loss) available to common stockholders, basic for fiscal 2021 was -$167.06M.
- PRAXIS PRECISION MEDICINES, INC. net income (loss) available to common stockholders, basic for fiscal 2020 was -$70.32M.
- PRAXIS PRECISION MEDICINES, INC. net income (loss) available to common stockholders, basic for fiscal 2019 was -$40.68M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$58.58M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$103.29M derived: sum of 2 quarters · filed 2022-02-28 | -$139.69M derived: sum of 3 quarters · filed 2022-02-28 | -$167.06M 10-K · filed 2022-02-28 |
| 2021-09-30 | -$44.70M 10-Q · filed 2021-11-03 | -$81.11M derived: sum of 2 quarters · filed 2021-11-03 | -$108.48M 10-Q · filed 2021-11-03 | -$135.13M derived: sum of 4 quarters · filed 2022-02-28 |
| 2021-06-30 | -$36.40M 10-Q · filed 2021-08-16 | -$63.77M 10-Q · filed 2021-08-16 | -$90.43M derived: sum of 3 quarters · filed 2022-02-28 | -$110.59M derived: sum of 4 quarters · filed 2022-02-28 |
| 2021-03-31 | -$27.37M 10-Q · filed 2021-05-11 | -$54.03M derived: sum of 2 quarters · filed 2022-02-28 | -$74.19M derived: sum of 3 quarters · filed 2022-02-28 | -$87.80M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-12-31 | -$26.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$46.81M derived: sum of 2 quarters · filed 2022-02-28 | -$60.42M derived: sum of 3 quarters · filed 2022-02-28 | -$70.32M 10-K · filed 2022-02-28 |
| 2020-09-30 | -$20.16M 10-Q · filed 2021-11-03 | -$33.77M derived: sum of 2 quarters · filed 2021-11-03 | -$43.67M 10-Q · filed 2021-11-03 | -$52.77M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | -$13.61M 10-Q · filed 2021-08-16 | -$23.51M 10-Q · filed 2021-08-16 | -$32.62M derived: sum of 3 quarters · filed 2021-08-16 | -$44.49M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | -$9.90M 10-Q · filed 2021-05-11 | -$19.01M derived: sum of 2 quarters · filed 2021-05-11 | -$30.88M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | -$9.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17 | -$20.98M derived: sum of 2 quarters · filed 2021-03-17 | -$40.68M 10-K · filed 2021-03-17 | |
| 2019-09-30 | -$11.87M 10-Q · filed 2020-11-23 | -$31.57M 10-Q · filed 2020-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |